Brexit / Uncertainty Still Reigns for UK Life Sciences
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get…
Address: St John’s Innovation Centre Cowley Road Cambridge CB4 0WS ,United Kingdom
Tel: + 44 (0) 1223 421411
Web: http://tiger.directrouter.co.uk/cgi-sys/defaultwebpage.cgi
Altacor is an Ophthalmic Specialty Pharmaceutical Company specialising in marketing and development of differentiated products which have been designed for the needs of both ophthalmologists and patients.
From its headquarters in Cambridge UK, Altacor is using its drug development skills and in depth market knowledge to build a portfolio of high quality, differentiated prescription medicines that set new standards in the sector. The company has a sales infrastructure which is active in the secondary care sector and in accessing primary care and promoting the prescription products Clinitas and Clinitas Gel. Altacor is also working in the pharmacy and optical channels through which its OTC products – the Clinitas range for all dry eye conditions, are being promoted.
Altacor’s pipeline consists of development products for Ocular Surface Disease, Ocular Infection and Glaucoma. The company’s products are differentiated by formulation or reprofiling, patented active or delivery systems and presented in multidose or preservative-free single use containers.
Altacor has strong skills in drug formulation, reprofiling and development through its extensive network and understanding of the European regulatory environment which results in a uniquely focused company.
Altacor has three areas of therapeutic interest
1. Ocular Surface Disease including Dry Eye syndrome
2. Ocular Infection
3. Glaucoma
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial asset on the market, a strong pipeline of development assets and a…
Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant. Although it is not…
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are…
The 9th February 2019 marked the launch of the European Medicines Verification System (EMVS) which will use cutting-edge technology to safeguard the medicine supply chain against fake products. Each European country…
In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on the up, but just in case we were becoming immune to these warnings, the UK has…
An unusual characteristic of the UK’s healthcare landscape is that charities fund the vast majority of medical research. According to the Association of Medical Research Charities (AMRC), in 2017, 8 million people…
The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint venture (JV) set to become the global market leader in over-the-counter (OTC) products…
Ian Chamberlain looks at the changing role of the pharma sales manager and the skills needed to keep up with new tech and the next generation of millennial sales reps. With…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In his second piece for PharmaBoardroom, Aditya examines the dangers of nationalism and populism for the private sector. The biggest global risk I see…
See our Cookie Privacy Policy Here